Lerociclib NEW
| Price | $32 | $73 | $123 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-12 |
Product Details
| Product Name: Lerociclib | CAS No.: 1628256-23-4 |
| Purity: 99.00% | Supply Ability: 10g |
| Release date: 2026/05/12 |
Product Introduction
Bioactivity
| Name | Lerociclib |
| Description | Lerociclib (G1T38) is a selective and highly potent CDK4/6 inhibitor with anticancer and antitumor activity, inhibits CDK4/CyclinD1 and CDK6/CyclinD3, and inhibits tumor growth in an animal model of endocrine-resistant breast cancer. Due to the poor solubility, for animal studies, the salt form T11345L is recommended. |
| In vitro | Lerociclib is highly potent and selective for CDK4/cyclin D1 and CDK6/cyclin D3 over CDK1, CDK2, CDK5 and CDK7 and their respective binding partners. Lerociclib produced a robust and sustained G1 arrest in CDK4/6 dependent cells with an EC50 of ~20 nmol/L. [1] |
| In vivo | To evaluate the murine PK/PD relationship of Lerociclib, an ER+ MCF7 xenograft model was utilized. Compound concentrations were measured in plasma and tumors from tumor-bearing mice given a single oral dose of Lerociclib (100 mg/kg). Oral Lerociclib has sufficient mouse PK/PD for assessing efficacy in tumor models. [1] |
| Storage | Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Lerociclib | CDK9/Cyclin T | CDK7/Cyclin H/MAT1 | cdk6/cyclin D3 | CDK6 | CDK5/p35 | Cdk5/p25 | Cdk4/cyclin D1 | CDK4 | CDK2/cyclinE | cdk2/cyclin A | CDK1/cyclinB1 |
| Inhibitors Related | Ribociclib | (E)-β-Farnesene | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | 2,4,6-Trihydroxybenzoic acid | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Seliciclib | Dinaciclib |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Approved Drug Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $31.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-21 | |
| $32.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY